Abstract
Interferon, one of the major defenses against viral infections, is produced by the body in small amounts on demand. However, its production can be stimulated by many different substances, both natural and synthetic, both small and large in molecular weight. This induction of interferon offers an alternative to the use in therapy of interferon that has been prepared by recombinant DNA technology. The purpose of this review is to describe briefly the structures of some known inducers of interferon, particularly the synthetic polymeric ones. Although the synthetic polynucleotides have shown the greatest promise in this regard, the possibilities for those inducers prepared from simpler monomer systems will be considered.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
A. Isaacs and J. Lindeman, Proc. Roy. Soc. B, 147, 258 (1957).
S. Pestka and S. Baron, Methods Enzymol., 78 (Interferons, Part A), 3 (1981).
3 D. A. J. Tyrrell, Nature, 184, 452 (1959).
S. Baron, F. Dianzani, and G. J. Stanton, Tex. Rep. Biol. Med., 41, 1 (1982).
G. J. Galasso and J. K. Dunnick, Tex Rep. Biol. Med., 35, 479 (1977).
T. C. Merigan, Tex. Rep. Biol. Med., 35, 541 (1977).
K. Cantell, S. Hirvonen, H. Kauppinen, and G. Myllyla, Methods Enzymol., 78 (Interferon, Pt. A), 29 (1981).
E. De Clercq, Methods Enzymol., 78 (Interferons, Pt. A), 227 (1981).
D. A. Stringfellow, “Interferons and Interferon Inducers”, Marcel Dekker, New York (1980).
A. Khan, N. O. Hill, and G. L. Dorn, “Inteferons: Properties and Clinical Uses”, LeLand Fikes, Dallas, TX (1980).
D. A. Stringfellow, Comprehensive Therapy, 3, 25 (1977).
S. Baron, P. A. Brunnell, and S. E. Grossberg in: “Antiviral Agents and Viral Diseases of Man”, G. J. Galasso, editor, Raven Press, New York, 1979, chapter 4.
E. R. Kern, and L. A. Glascow, Pharmac. Ther., 13, 1 (1981).
G. J. Minks, Microbiol. Rev., 45, 244 (1981).
Y. Inaki and K. Takemoto, Kagaku (Kyoto), 31, 908 (1976).
H. B. Levy in: “Polymeric Drugs [Proc. Int. Symp.]”, L. G. Donaruma and O. Vogl, eds., Academic Press, New York, 1978, p. 305.
M. C. Breinig and P. S. Morahan, Mod. Pharmacol.-Toxicol., 17 (Interferon Interferon Inducers: Clin. Appl.), 239 (1980).
P. B. Sehgal, L. M. Pfeiffer, and I. Tamm, Handb. Exp. Pharmacol., 61 (Chemother. Viral Infect.), 205 (1982).
S. Hoffman, Z. Chem., 22, 357 (1982).
P. F. Torrence and E. DeClercq, Handb. Exp. Pharmacol., 71 (Interferons: Their Appl.), 233 (1984).
S. E. Grossberg, Tex. Rep. Biol. Med., 35 (Interferon Syst.), 111 (1977).
W. E. Stewart II, Tex. Rep. Biol. Med., 41, 271 (1982).
P. F. Torrence and E. De Clercq, Methods Enzymol., 78, 271 (1982).
J. Pitha and P. M. Pitha, Science, 172, 1146 (1971).
J. Pitha and J. W. Kusiak in: “Anticancer and Interferon Agents”, Marcel Dekker, New York, 1984.
P. De Somer, E. De Clercq, A. Billiau, E. Schonne, and M. Claesen, J. Virol., 2, 886 (1968).
T. C. Merigan and M. S. Finkelstein, Virology, 35, 363 (1968).
T. C. Merigan and W. Regelson, N. Eng. J. Med., 277, 1283 (1967).
E. De Clercq and M. Luczak, Arch. Virol., 52, 151 (1976).
P. Claes, A. Billiau, E. De Clercq, J. Desmyter, E. Schonne, H. Vanderhaehge, and P. De Somer, J. Virol., 5, 313 (1970).
F. I. Ershov, K. V. Moschik, A. M. Poverennyi, V. K. Podgorod-nichenko, and G. A. Popov, Byull. Eksp. Biol. Med., 94, 76 (1982).
S. Suzuki, Japan Kokai 76 41, 083 06 Apr. 1976.
O. G. Andzhaparidge, T. A. Bektemirov, M. P. Burgasova, and K. Y. Oglezner, Vopr. Virusol., 4, 407 (1981).
E. De Clercq, Tex. Rep. Biol. Med., 35, 29 (1977).
V. D. Kol’tsor, L. V. Krasnova, I. G. Balandin, and E. N. Meshkova, Byull. Eksp. Biol. Med., 95, 74 (1983).
H. B. Levy, F. L. Riley, E. Lvovsky, and E. E. Stephen, Infect. Immun., 34, 416 (1981).
E. De Clercq, B. D. Stollar, and M. N. Thang, J. Gen. Virol., 40, 203 (1978).
E. De Clercq, P. E. Torrence, B. D. Stollar, J. Hobbs, T. Fukai, N. Kakiuchi, and M. Ikehara, Eur. J. Biochem., 88, 341 (1978).
Tokuyama Soda Co., Ltd., Jpn. Kokai Tokyo Koho JP 59 70, 618 [84 70, 618] 21 Apr. 1984.
F. I. Ershov, A. N. Fomina, V. F. Krylov, N. P. Obrosova-Serova, S. S. Grigoryan A. N. Slepushkin, K. V. Moshchik, V. I. Balashov, I. A. Grusinskaya, and N. A. Smagulova, Vopr. Virusol., 4, 418, 423 (1981).
H. B. Methods. Enzymol., 78 (Interferons, Part A), 242 (1981).
K. Reuss, K. H. Scheit and O. Saiko, Nucleic Acids Res., 3, 2861 (1976).
P. F. Torrence, E. De Clercq, J. A. Walters, and B. Witkop, Biochemistry, 13, 4400 (1974).
E. De Clercq, B. D. Stoller, J. Hobbs, T. Fukui, N. Kakiuchi, and M. I. Kehara, Eur. J. Biochem., 107, 279 (1980).
A. S. Levine, M. Sivulich, P. H. Wiernik, and H. B. Levy, Cancer Res., 39, 1645 (1979).
H. B. Levy, and F. L. Riley, U. S. Patent Appl. US 292, 583, 18 June 1982.
K. Wasche, S. R. Wasche, S. Hoffman, and W. Witkowski, Acta Biol. Med. Ger., 38, 739 (1979).
P. M. Pitha, Tex. Rep. Biol. Med., 35 (Interferon Syst.), 39 (1977).
P. M. Pitha, Methods Enzymol., 78 (Interferons, Part A), 236 (1981).
D. F. Bradley, J. Macromol. Sci.-Chem., A4, 741 (1970).
A. E. Munson, K. L. White, and P. C. Klykken in: “Augmenting Agents in Cancer Therapy”, E. M. Hersh, ed., Raven Press, New York, 1981, p. 329.
R. S. McCord, M. K. Breinig, and P. S. Morahan, Antimicrobial Agents and Chemotherapy, 10, 28, (1976).
D. S. Breslow, Pure and Appl. Chem., 46, 103 (1976).
R. A. Carrano, F. K. Kinoshita, A. R. Imondi, and J. D. Iuliucci in “Augmenting Agents in Cancer Therapy”, Progress in Cancer Research, Vol. 16, E. M. Hersh, ed., Raven Press, New York, 1981, p. 345.
E. M. Hodnett, Polymer News, 8, 162 (1982).
S. Hoffman, W. Witkowsky, K. Wasche, and S. R. Wasche, Z. Chem., 17, 61 (1977).
S. Hoffman, W. Witkowsky, and K, Wasche, Z. Chem., 16, 484 (1976).
P. J. Grob, H. I. Joller-Jemelka, U. Binswanger, K. Zarba, C. Descoeudres, and M. Fernex, Eur. J. Clin. Microbiol., 3, 195 (1984).
L. Gros, H. Ringsdorf, and H. Schupp, Angew. Chem. Int. Ed. Engl., 20, 305 (1981).
P. S. Morahan in: “Augmenting Agents in Cancer Therapy”, Progress in Cancer Research, Vol. 16, E. M. Hersh, ed., Raven Press, New York, 1981, p. 185.
E. M. Hodnett, Polymer News, 8, 323 (1983).
L. G. Donaruma, Progress Polymer Sci., 4, 1 (1974).
“Polymers in Biology and Medicine, Vol. I, Anionic Polymeric Drugs”, L. G. Donaruma, R. M. Ottenbrite, and O. Vogl, eds., John Wiley, New York, 1980.
W. Regelson, Adv. Chemother., 3, 303 (1968).
W. Regelson in: “Water-Soluble Polymers”, N. M. Bikales, editor, Plenum Press, 1973, p. 161.
W. Regelson, J. Polymer Science, Polymer Symposium, 66, 483 (1979).
“Biological Activities of Polymers”, C. E. Carraher, Jr. and C. G. Gebelein, editors, ACS Series 186, American Chemical Society, Washington, DC, 1982.
R. M. Ottenbrite, and G. G. Butler in: “Anticancer and Interferon Agents”, Marcel Dekker, New York, 1984.
P. O. P. Ts’o, P. S. Miller, and J. J. Greene, Prog. Cancer Res. Ther., 28 (Dev. Target-Oriented Anticancer Drugs), 189 (1983).
W. Regelson, S. Kuhar, M. Tunis, J. Fields, J. Johnson, and E. Glusenkamp, Nature, 186, 778 (1960).
E. M. Hodnett and J. Tien Hai Tai, J. Med. Chem., 17, 1335 (1974).
E. M. Hodnett, J. Amirmoazzami, and J. Tien Hai Tai, J. Med. Chem., 21, 652 (1978).
E. M. Hodnett, A. Wai Woo, and F. A. French, Eur. J. Med. Chem., 13, 652 (1978).
J. H. Dean, M. L. Padarathsingh, and L. Kays, Cancer Treatment Reports, 62, 1807 (1978).
P. S. Morahan, D. W. Barnes, and A. E. Munson, Cancer Treatment Reports, 62, 1797 (1978).
N. A. Pavlidis, R. M. Schaltz, M. A. Chirigos, and J. Luetzeler, Cancer Treatment Reports, 62, 1817 (1978).
M. A. Chirigos and W. A. Stylos, Cancer Res., 40, 1967 (1980).
R. Ottenbrite, E. Goodell, and A. Munson, Polymer, 18, 461 (1977).
R. L. Stofi and D. S. Martin, Cancer Treatment Reports, 62, 1791 (1978).
S. J. Mohr, M. A. Chirigos, F. S. Fuhrman, and J. W. Pryor, Cancer Res., 35, 3750 (1978).
W. Wierenga, Ann. Rep. Med. Chem., 17, 151 (1982).
E. De Clercq and P.F. Torrence, Tex. Rep. Biol. Med., 41, 76 (1982).
D. R. Stryer, W. A. Carter, D. H. Gillespie, I. Brodsky, C. Baglioni, J. M. Zarling, J. J. Greene, and P. O.P. Ts’o, Proc. Am. Assn. Cancer Res., 22, 160 (1981).
E. De Clercq, Antibiotics Chemother., 27, 251 (1980).
H. B. Levy, E. Lvovsky, F. Riley, D. Harrington, A. Anderson, J. Moe, J. Hilfenhaus, and E. Stephen, Ann. N. Y. Acad. Sci., 350, 33 (1980).
R. F. Oldham, Cancer Treat. Rep., 68, 221 (1984).
P. S. Sunkara, N. J. Prakash, A. L. Rosenberger, A. C. Hagan, P. J. Lachmann, and G. D. Mayer, Cancer Res., 44, 2799 (1984).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Springer Science+Business Media New York
About this chapter
Cite this chapter
Hodnett, E.M. (1985). Synthetic Polymeric Inducers of Interferon. In: Gebelein, C.G., Carraher, C.E. (eds) Polymeric Materials in Medication. Polymer Science and Technology, vol 32. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-2245-8_19
Download citation
DOI: https://doi.org/10.1007/978-1-4899-2245-8_19
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-2247-2
Online ISBN: 978-1-4899-2245-8
eBook Packages: Springer Book Archive